US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

ホーム
投資
株式
アメリカ
NYSE
Novartis AG (NVS)
Novartis AG (NVS) ニュース

NVS

Novartis (NVS)

Novartis AG

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:NVS

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/04/23	20 : 25	IH Market News	Apple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More News	NYSE:NVS	Novartis AG
2024/04/16	03 : 00	PR Newswire (US)	New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)	NYSE:NVS	Novartis AG
2024/04/11	20 : 00	GlobeNewswire Inc.	Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer	NYSE:NVS	Novartis AG
2024/04/10	20 : 13	IH Market News	Delta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News	NYSE:NVS	Novartis AG
2024/04/07	05 : 16	PR Newswire (US)	New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting	NYSE:NVS	Novartis AG
2024/02/16	06 : 15	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NYSE:NVS	Novartis AG
2024/02/07	06 : 52	Edgar (US Regulatory)	Form SC TO-C - Written communication relating to an issuer or third party	NYSE:NVS	Novartis AG
2024/02/06	20 : 14	IH Market News	Boeing Faces Strike Threat, Palantir Up 18% After Recording its First Profitable Year, and More	NYSE:NVS	Novartis AG
2024/02/06	07 : 06	Edgar (US Regulatory)	Form SC TO-C - Written communication relating to an issuer or third party	NYSE:NVS	Novartis AG
2024/02/03	04 : 18	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NYSE:NVS	Novartis AG
2024/01/31	21 : 44	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NYSE:NVS	Novartis AG
2024/01/31	21 : 43	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NYSE:NVS	Novartis AG
2024/01/31	21 : 42	Edgar (US Regulatory)	Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).	NYSE:NVS	Novartis AG
2024/01/31	21 : 38	Edgar (US Regulatory)	Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]	NYSE:NVS	Novartis AG
2024/01/31	20 : 28	IH Market News	Walmart’s Stock Split, Elon Musk’s Billion-Dollar Package Revoked, and More	NYSE:NVS	Novartis AG
2024/01/22	15 : 59	Dow Jones News	Sandoz to Acquire Cimerli Business from Coherus for $170 Million	NYSE:NVS	Novartis AG
2024/01/12	20 : 10	IH Market News	Wall Street Highlights: DocuSign Acquisition Battle, Tesla Berlin Production Halt, and More	NYSE:NVS	Novartis AG
2024/01/12	03 : 02	Dow Jones News	Cytokinetics Shares Slide as Novartis Reportedly Shies Away From Deal	NYSE:NVS	Novartis AG
2024/01/09	03 : 43	Dow Jones News	Cytokinetics Shares Jump 16% After WSJ Report of Novartis Deal	NYSE:NVS	Novartis AG
2024/01/09	00 : 41	Dow Jones News	Novartis on Track for Record High Close -- Data Talk	NYSE:NVS	Novartis AG
2024/01/08	20 : 13	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NYSE:NVS	Novartis AG
2024/01/08	16 : 01	Dow Jones News	Novartis's Scemblix Drug Meets Main Goals in Late-Stage Leukemia Trial	NYSE:NVS	Novartis AG
2024/01/06	00 : 15	Dow Jones News	Novartis to Make Pluvicto Radioligand Therapy at Indianapolis Plant	NYSE:NVS	Novartis AG
2024/01/02	21 : 46	Dow Jones News	Voyager Therapeutics Shares Leap Premarket on Novartis Collaboration	NYSE:NVS	Novartis AG
2023/12/11	20 : 05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NYSE:NVS	Novartis AG
2023/12/11	16 : 02	Dow Jones News	Novartis Drug Meets Primary Goal in Late-Stage Study for Kidney Disease	NYSE:NVS	Novartis AG
2023/12/11	09 : 39	PR Newswire (US)	Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)	NYSE:NVS	Novartis AG
2023/12/06	19 : 14	Dow Jones News	Merck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage Trials	NYSE:NVS	Novartis AG
2023/12/06	14 : 18	PR Newswire (US)	Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH	NYSE:NVS	Novartis AG
2023/12/05	20 : 25	IH Market News	Moody’s Reassesses China, GitLab Exceeds Estimates, Twilio Plans Major Layoffs, and More	NYSE:NVS	Novartis AG

Showing the most relevant articles for your search:NYSE:NVS

1 2 3 4 5 6 7 8 9 10 次へ >>

Bank of America

Invesco QQQ Trust Series 1

Deutsche Telekom (QX)

US Dollar vs Euro

JP Morgan Chase

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約